Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually Transcript - Thomson StreetEvents

Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually Transcript

Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually Transcript - Thomson StreetEvents
Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually Transcript
Published Jun 30, 2021
53 pages (38634 words) — Published Jun 30, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of APLS.OQ corporate analyst meeting

  
Brief Excerpt:

...All right. Hello? Hello? Okay. How does it feel to be at a live event? Feels good to me. All right. Well, welcome, everyone, to Apellis' R&D Day. It's an incredible joy to have you all with us here in person and the people following on the web. Before we get started, I think it is worth kind of taking a step back to the year 2017 in November when we went public. That makes us, I guess, 4 years old as a public company, which makes us like senior citizens in the IPO world of today. And -- but looking at that moment in 2017 after -- just after we had gone public, and we sat down and determined that it would be our singular mission to become the world's heavyweight champions of complement. And that wasn't because we were being arrogant, because we understand...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Apellis Pharmaceuticals Inc
Ticker
APLS.OQ
Time
4:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Matthew W. Luchini - BMO Capital Markets Equity Research - Analyst : Matthew Luchini from BMO. Just was hoping you could talk a little bit -- you obviously have patients from the study that are on Empaveli now. If you could tell us a little bit about how your nontrial patients are planning to be switched, if at all and what -- how much of that will be patient request-driven versus you sort of poking and prodding? Just any additional color on how you think your treatment breakdown may compare today versus, let's say, end of the year or a year from now? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Table Of Contents

Apellis Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-10 – US$ 54.00 – Edited Transcript of APLS.OQ presentation 10-Jan-22 1:15pm GMT

Apellis Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript – 2021-11-10 – US$ 54.00 – Edited Transcript of APLS.OQ presentation 10-Nov-21 9:20pm GMT

Apellis Pharmaceuticals Inc Q3 2021 Earnings Call Transcript – 2021-11-08 – US$ 54.00 – Edited Transcript of APLS.OQ earnings conference call or presentation 8-Nov-21 9:30pm GMT

Apellis Pharmaceuticals Inc Announces results from Phase 3 DERBY and OAKS Transcript – 2021-09-09 – US$ 54.00 – Edited Transcript of APLS.OQ conference call or presentation 9-Sep-21 8:30pm GMT

Apellis Pharmaceuticals Inc Q2 2021 Earnings Call Transcript – 2021-08-09 – US$ 54.00 – Edited Transcript of APLS.OQ earnings conference call or presentation 9-Aug-21 8:30pm GMT

Apellis Pharmaceuticals Inc at Bank of America NAPA Healthcare Conference Transcript – 2021-06-16 – US$ 54.00 – Edited Transcript of APLS.OQ presentation 16-Jun-21 8:30pm GMT

Apellis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript – 2021-06-10 – US$ 54.00 – Edited Transcript of APLS.OQ presentation 10-Jun-21 12:00pm GMT

Apellis Pharmaceuticals Inc EMPAVELI FDA Approval Call Transcript – 2021-05-17 – US$ 54.00 – Edited Transcript of APLS.OQ conference call or presentation 17-May-21 12:00pm GMT

Apellis Pharmaceuticals Inc Q1 2021 Earnings Call Transcript – 2021-04-28 – US$ 54.00 – Edited Transcript of APLS.OQ earnings conference call or presentation 28-Apr-21 8:30pm GMT

Apellis Pharmaceuticals Inc Q4 2020 Earnings Call Transcript – 2021-02-25 – US$ 54.00 – Edited Transcript of APLS.OQ earnings conference call or presentation 25-Feb-21 9:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually Transcript" Jun 30, 2021. Alacra Store. May 03, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Apellis-Pharmaceuticals-Inc-Research-and-Development-Day-New-York-City-and-Virtually-T14899299>
  
APA:
Thomson StreetEvents. (2021). Apellis Pharmaceuticals Inc Research and Development Day - New York City and Virtually Transcript Jun 30, 2021. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Apellis-Pharmaceuticals-Inc-Research-and-Development-Day-New-York-City-and-Virtually-T14899299>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.